Episode Details

A breakthrough drug called daraxonrasib is giving advanced pancreatic cancer patients a fighting chance—offering nearly double the survival time compared to standard chemo. Targeting a long-elusive mutated protein, the pill acts like molecular glue to halt tumor growth, bringing hope to a disease once deemed “undruggable.” Doctors were moved by how it improved patients’ quality of life, even as the drug’s effects waned. With FDA fast-tracking approval and early use being explored before surgery, this could redefine treatment—and the results, published in the New England Journal of Medicine, are already sparking excitement in the cancer community.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/c77d26af94bf02f3